Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (441-450 of 463) with videos related to

Pageof 47
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative ColitisDivya Jha, Zainab Al-Taie, Azra Krek, et al.
Gut|November 1, 2016
Development of an index to define overall disease severity in IBDCorey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Gastroenterology|May 27, 2022
Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn's DiseaseArthur Mortha, Romain Remark, Diane Marie Del Valle, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 13, 2024
Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert ConsensusSerre-Yu Wong, Cathy Rowan, Elvira Diaz Brockmans, et al.
Journal of Crohn'S & Colitis|September 28, 2023
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis SubtypesTenghao Zheng, Giulia Roda, Yamile Zabana, et al.
Gastroenterology|June 2, 2018
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's DiseaseParambir S Dulai, Brigid S Boland, Siddharth Singh, et al.
Pageof 47

Showing results (441-450 of 463) with videos related to

Sort By:
Pageof 47
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
Inflammatory Bowel Diseases|May 4, 2019
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease OutcomesJenna L Koliani-Pace, Siddharth Singh, Michelle Luo, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative ColitisDivya Jha, Zainab Al-Taie, Azra Krek, et al.
Gut|November 1, 2016
Development of an index to define overall disease severity in IBDCorey A Siegel, Cynthia B Whitman, Brennan M R Spiegel, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Gastroenterology|May 27, 2022
Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn's DiseaseArthur Mortha, Romain Remark, Diane Marie Del Valle, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 13, 2024
Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert ConsensusSerre-Yu Wong, Cathy Rowan, Elvira Diaz Brockmans, et al.
Journal of Crohn'S & Colitis|September 28, 2023
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis SubtypesTenghao Zheng, Giulia Roda, Yamile Zabana, et al.
Gastroenterology|June 2, 2018
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's DiseaseParambir S Dulai, Brigid S Boland, Siddharth Singh, et al.
Pageof 47